1. Home
  2. GKOS vs BGC Comparison

GKOS vs BGC Comparison

Compare GKOS & BGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$107.89

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo BGC Group Inc.

BGC

BGC Group Inc.

HOLD

Current Price

$8.73

Market Cap

4.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
BGC
Founded
1998
1945
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
4.4B
IPO Year
2015
1999

Fundamental Metrics

Financial Performance
Metric
GKOS
BGC
Price
$107.89
$8.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
2
Target Price
$122.08
$14.50
AVG Volume (30 Days)
1.1M
2.9M
Earning Date
10-29-2025
11-06-2025
Dividend Yield
N/A
0.93%
EPS Growth
N/A
36.46
EPS
N/A
0.33
Revenue
$469,820,000.00
$2,640,884,000.00
Revenue This Year
$30.89
$35.74
Revenue Next Year
$24.36
$11.43
P/E Ratio
N/A
$25.93
Revenue Growth
30.38
24.59
52 Week Low
$73.16
$7.24
52 Week High
$163.71
$10.96

Technical Indicators

Market Signals
Indicator
GKOS
BGC
Relative Strength Index (RSI) 73.56 45.57
Support Level $104.11 $8.52
Resistance Level $107.18 $8.76
Average True Range (ATR) 4.40 0.22
MACD 1.26 0.01
Stochastic Oscillator 92.97 50.22

Price Performance

Historical Comparison
GKOS
BGC

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About BGC BGC Group Inc.

BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.

Share on Social Networks: